Profound MedicalPROF
Recorded

Profound Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to Profound Medical Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Stephen Kilmer, Investor Relations.

Stephen KilmerInvestor Relations Contact

Thank you, operator, and good afternoon, everyone. Welcome to Profound Medical's Third Quarter 2026 Conference Call. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the U.S. and Canada. All forward-looking statements are based on Profound's current beliefs, assumptions, and expectations. They relate to, among other things, current or future financial performance and position, our revenue and gross margin outlook, commercialization activities, customer utilization, product development, leadership succession, and expectations regarding the efficacy of our technologies. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. No forward-looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these statements, which speak only as of today.

Stephen KilmerInvestor Relations Contact

Please review the risk factors described in our filings with the U.S. and Canadian securities regulators. Profound undertakes no obligation to publicly update or revise forward-looking statements, except as required by law. Joining us today are Dr. Arun Menawat, Chief Executive Officer and Chairman, Matthew Sobczyk, our Chief Financial Officer, Tom Tamberrino, Chief Commercial Officer, Mathieu Burtnyk, our Chief Technology Officer, and Richard Fabian, our current President and incoming CEO. We have lots to discuss today. Matthew will begin with our financial results, followed by Rich on operational priorities and Tom on commercial progress. Arun will then provide a strategic update before we open the call to questions. Just a heads-up in that regard, Arun is just getting over a bad cold, so his voice might break up a bit here and there. With that, I'll turn the call over to Matthew.

Matthew SobczykCFO

Good afternoon, everyone. On behalf of the management team and everyone at Profound, thank you for your continued interest and support. Before turning the call over to Rich for an operational update, I'll briefly review our third quarter 2026 financial results. For the three months ended September 30, 2026, Profound recorded total revenue of $9.8 million, up 86% from the third quarter of 2025. Revenue comprised $4.1 million of recurring non-capital revenue from single-use devices and service associated with extended warranties, and $5.7 million of capital equipment sales. Gross margin was 78% compared with 74% in the prior year quarter, reflecting a favorable product mix and continued strong price discipline. Operating expenses were $15.5 million, an increase of 21% year-over-year.

Matthew SobczykCFO

The increase primarily reflected increased headcount, increased commission expense driven by our revenue growth, travel expenditures, and higher consulting expenditures due to spending on R&D initiatives to reduce product cost and improve efficiencies. These were partially offset by a reduction in the clinical trial costs due to CAPTAIN trial enrollment completion. Our net loss improved by 3% to approximately $7.7 million, or $0.21 per common share, compared with approximately $8 million, or $0.26 per common share, in the third quarter of 2025. Cash used in operating activities was $5 million. This was down 56% sequentially from $11.3 million in the second quarter of 2026, and down 48% from $9.6 million in the third quarter of last year. We ended September with approximately $33.3 million in cash. As of today, we have 36,626,844 common shares outstanding.

Matthew SobczykCFO

Based on our results through September and our expectations for the remainder of the year, we are projecting our full 2026 revenue to be at least $25 million and gross margin to be 70% or higher. As we noted in today's press release, we expect existing cash and revenue from product and service sales to be sufficient to fund our operating and capital expenditure requirements for at least the next 12 months. While we have no immediate plans to raise capital, we will opportunistically evaluate both dilutive and non-dilutive financing opportunities that support our path to profitability while balancing our capital needs with shareholder dilution. Our capital allocation priorities are to support commercial execution, improve efficiencies, and strengthen the operating capabilities needed as the business grows. We will continue to assess those investments against our financial resources and our goal of building a profitable growth business.

Matthew SobczykCFO

With that, I'll turn the call over to Rich.

Richard FabianPresident and Incoming CEO

Thank you, Matthew, and good afternoon, everyone. I appreciate the confidence Arun and the board have placed in me. I look forward to leading Profound as CEO and working with Arun as executive chairman beginning in mid-January. Arun has played an invaluable role in guiding TULSA-PRO through FDA clearance, CMS reimbursement, and into commercial adoption. We have a platform with an established clinical evidence base, a growing commercial opportunity, and the ability to generate recurring revenue as customers perform procedures. My priority is to scale this organization and help translate that into consistent execution. First, we need to convert our commercial pipeline into placements. That means disciplined management of opportunities, clear customer economics, and coordinated work across sales, installation, and support. Cook Medical adds another key channel, and our job is to make that relationship productive alongside our direct sales activities. Second, we need to help customers increase utilization.

Richard FabianPresident and Incoming CEO

Each additional productive system creates an opportunity to grow recurring revenue and strengthen the economics of our business. A placement is the beginning of a customer relationship, and the work that follows is critical. We are focused on the practical elements of a successful program: physician engagement, training, scheduling, referral development, and coordination within the facility, with support available when customers need it, particularly as they begin treating patients. Third, we need to improve operating efficiencies as we scale. Our engineering investments are directed towards better, faster TULSA procedures, while also creating opportunities to continue to reduce costs further over time. As we plan for 2027, we will assess additional investment in utilization support and program startup, with financial discipline and clear performance expectations. I also see value in continuing to build our relationships across the imaging and physician communities. Interventional MRI is an important part of Profound's strategy.

Richard FabianPresident and Incoming CEO

Our immediate task is to make TULSA programs work well for customers today while developing the capabilities that may expand the platform's value in the future. The third quarter provides an encouraging foundation: higher revenue, strong gross margin, and reduced operating cash use. Our focus is to build on the progress and move Profound towards sustainable, profitable growth. Now, I am pleased to pass the call over to Tom.

Tom TamberrinoChief Commercial Officer

Thank you, Rich, and good afternoon. As Rich just discussed, our commercial priorities are to convert qualified opportunities into placements and help each installed customer build a productive TULSA program. At the end of the third quarter, our TULSA-PRO installed base was 98 systems. We also just reached an important existing system utilization milestone with the 5,000th TULSA procedure performed in October. Our qualified sales pipeline for TULSA-PRO and Sonalleve totaled approximately $79.2 million at quarter end. As on previous calls, qualified opportunities are those in the verify, negotiate, or contracting stages. The pipeline is a measure of opportunity, and there can be no assurance regarding the extent or timing of its conversion into recognized revenue.

Tom TamberrinoChief Commercial Officer

As Rich mentioned, we added a key new distribution channel for TULSA products under a supply and distribution agreement signed last week with Cook Medical, one of the largest privately held medical device manufacturers in the U.S. The structure is important. Cook will purchase TULSA-PRO systems at a predetermined transfer price. Customers who purchase systems through Cook will obtain their disposables and service contracts directly from Profound. This strongly complements our own sales team's continued focus on selling TULSA-PRO for existing 1.5 Tesla and three Tesla MRI systems, which are outside the agreement scope, while preserving our direct relationships for disposables and service with U.S. customers, no matter how they obtain TULSA-PRO systems. Cook's work in interventional MRI provides a great foundation for the upcoming launch.

Tom TamberrinoChief Commercial Officer

As some of you may know, among other things, Cook is one of the largest manufacturers of MR-compatible biopsy systems and needles, so our deal perfectly aligns with their view that purpose-built iMRI environments can help expand access to image-guided procedures. We will update investors separately on product integration and regulatory milestones as appropriate. Payer coverage is another important part of making a system productive. in that regard, Profound continues to see meaningful progress in commercial payer engagement for the TULSA procedure. In the third quarter of 2026 alone, there were approximately 10.7 million covered lives added through commercial and government payers. Of those, approximately 1.8 million were added from commercial and Medicare Advantage programs. Of course, coverage alone does not ensure utilization. Programs also need clear referral pathways, coordinated scheduling, and efficient workflows.

Tom TamberrinoChief Commercial Officer

Our work with payers and providers focuses on expanding coverage where needed and helping customers navigate patient access. We believe we have a strong growth opportunity ahead of us, and as Rich described, we will invest further in our customer support teams as the installed base grows. Our objective is to help customers move more efficiently from installation to initial procedures, and then to a sustainable treatment schedule. We will also continue to use clinical education to support adoption. The growing evidence base, the recent symposium presentations, and our co-education partnership with Telix create opportunities to engage physicians on treatment planning and the clinical role of TULSA. To summarize, the commercial opportunity is substantial. Our team is focused on converting interest into customer decisions and helping those customers treat patients consistently. I will now turn the call over to Arun.

Arun MenawatCEO and Chairman

Thank you, Tom, and good afternoon, everyone. Today, our company is evolving rapidly. We believe that hurdles to change are dropping, and a substantive opportunity to grow is upon us. I am honored and delighted that Rich has joined us to lead the next phase of growth, and I welcome him on behalf of the board of the company. Rich, Tom, and Matthew already make a triple-A level team and give us great confidence in Profound's future. My presentation today is a bit longer than normal. The market for prostate care is evolving, and we believe we are well-positioned for the future in this era of change. I will describe the technical and financial foundation of our company, as well as go over the implications of new industry agreements that we have signed in terms of their potential contributions on growth of our company.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day